The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | The future of AML treatment? Progress in IDH1/2 inhibitors for AML
The development of IDH inhibitors for acute myeloid leukemia (AML) has been a smoother journey than that for FLT3 inhibitors. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, provides a comprehensive summary of the use of IDH inhibitors for acute myeloid leukemia (AML) treatment. Dr Stone covers the successful trial and subsequent approval of enasidenib for IDH2-mutated advanced AML, as well as the highly anticipated results of a trial investigating ivosidenib monotherapy for IDH1-mutated AML that were presented at the meeting (NCT02074839). Furthermore, he highlights exciting further trials of these drugs in combination regimens that were presented at the meeting (NCT02632708, NCT02677922).
